Entrada Therapeutics (TRDA) Operating Margin (2023 - 2026)

Entrada Therapeutics' Operating Margin history runs 4 years deep, the most recent figure standing at 4834.63% for Q1 2026.

• In Q1 2026, Operating Margin fell 472864.0% year-over-year to 4834.63%; the TTM figure through Mar 2026 stood at 3109.29% (down 311167.0% YoY), while the FY2025 annual figure was 621.13%, down 64344.0% from the prior year.
• Operating Margin was 4834.63% for Q1 2026 at Entrada Therapeutics, down from 3249.27% in the prior quarter.
• In the past five years, Operating Margin ranged from a high of 56.42% in Q2 2024 to a low of 4834.63% in Q1 2026.
• Historically, Operating Margin has averaged 1046.97% across 4 years, with a median of 89.7% in 2023.
• The sharpest annual moves came in 2024 and 2026: Operating Margin jumped 14612 bps in 2024, then plunged 472864 bps in 2026.
• A 4-year view of Operating Margin shows it stood at 11.72% in 2023, then tumbled by 234 bps to 15.69% in 2024, then tumbled by 20612 bps to 3249.27% in 2025, then slumped by 49 bps to 4834.63% in 2026.
• The last three Operating Margin figures came in at 4834.63% (Q1 2026), 3249.27% (Q4 2025), and 2915.18% (Q3 2025), per Business Quant data.